Evaxion Biotech A/S Q2 2023 Earnings Report $0.88 -0.08 (-7.98%) (As of 03:22 PM ET) Earnings HistoryForecast Evaxion Biotech A/S EPS ResultsActual EPS-$2.10Consensus EPS -$2.20Beat/MissBeat by +$0.10One Year Ago EPSN/AEvaxion Biotech A/S Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEvaxion Biotech A/S Announcement DetailsQuarterQ2 2023Date8/22/2023TimeQ2 2023 Earnings ReleaseConference Call ResourcesConference Call TranscriptEVAX Earnings History Affordable AI Plays: 2 Stocks Under $10 with Huge Potential! (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Evaxion Biotech A/S Earnings HeadlinesEvaxion Biotech pursues agreement with EIB to bolster equityDecember 17 at 9:22 PM | markets.businessinsider.comEvaxion Biotech: Evaxion establishes new AI-derived precision cancer vaccine conceptDecember 13, 2024 | finanznachrichten.deHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.December 18, 2024 | Insiders Exposed (Ad)Evaxion Biotech establishes new Ai-derived precision cancer vaccine conceptDecember 13, 2024 | markets.businessinsider.comEvaxion establishes new AI-derived precision cancer vaccine conceptDecember 12, 2024 | markets.businessinsider.comFinancial Analysis: Cortexyme (NASDAQ:CRTX) vs. Evaxion Biotech A/S (NASDAQ:EVAX)December 12, 2024 | americanbankingnews.comSee More Evaxion Biotech A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evaxion Biotech A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evaxion Biotech A/S and other key companies, straight to your email. Email Address About Evaxion Biotech A/SEvaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.View Evaxion Biotech A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
